8108 related articles for article (PubMed ID: 16078447)
41. Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.
Redman BG; Flaherty L; Chou TH; Nakeff A; Pillote K; Kaplan J
J Immunother (1991); 1991 Apr; 10(2):147-51. PubMed ID: 2043595
[TBL] [Abstract][Full Text] [Related]
42. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.
Kirkwood JM; Richards T; Zarour HM; Sosman J; Ernstoff M; Whiteside TL; Ibrahim J; Blum R; Wieand S; Mascari R
Cancer; 2002 Sep; 95(5):1101-12. PubMed ID: 12209697
[TBL] [Abstract][Full Text] [Related]
43. Biochemotherapy of metastatic malignant melanoma. On down-regulation of CD28.
Håkansson A; Håkansson L; Gustafsson B; Krysander L; Rettrup B; Ruiter D; Bernsen MR
Cancer Immunol Immunother; 2002 Nov; 51(9):499-504. PubMed ID: 12357321
[TBL] [Abstract][Full Text] [Related]
44. Impaired perforin-dependent NK cell cytotoxicity and proliferative activity of peripheral blood T cells is associated with metastatic melanoma.
Jović V; Konjević G; Radulović S; Jelić S; Spuzić I
Tumori; 2001; 87(5):324-9. PubMed ID: 11765182
[TBL] [Abstract][Full Text] [Related]
45. Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma.
Heise R; Amann PM; Ensslen S; Marquardt Y; Czaja K; Joussen S; Beer D; Abele R; Plewnia G; Tampé R; Merk HF; Hermanns HM; Baron JM
PLoS One; 2016; 11(1):e0146325. PubMed ID: 26735690
[TBL] [Abstract][Full Text] [Related]
46. The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy.
Hernberg M; Muhonen T; Turunen JP; Hahka-Kemppinen M; Pyrhönen S
J Clin Oncol; 1996 May; 14(5):1690-6. PubMed ID: 8622089
[TBL] [Abstract][Full Text] [Related]
47. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma.
Critchley-Thorne RJ; Yan N; Nacu S; Weber J; Holmes SP; Lee PP
PLoS Med; 2007 May; 4(5):e176. PubMed ID: 17488182
[TBL] [Abstract][Full Text] [Related]
48. [After removal of a malignant melanoma. Enhancing the immune system!].
MMW Fortschr Med; 1999 Nov; 141(44):66. PubMed ID: 10912153
[No Abstract] [Full Text] [Related]
49. Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy.
Hernberg M; Turunen JP; Muhonen T; Pyrhönen S
J Immunother; 1997 Nov; 20(6):488-95. PubMed ID: 9409455
[TBL] [Abstract][Full Text] [Related]
50. Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression.
Faião-Flores F; Quincoces Suarez JA; Fruet AC; Maria-Engler SS; Pardi PC; Maria DA
PLoS One; 2015; 10(3):e0118702. PubMed ID: 25742310
[TBL] [Abstract][Full Text] [Related]
51. A combination of photodynamic therapy and chemotherapy displays a differential cytotoxic effect on human metastatic melanoma cells.
Biteghe FN; Davids LM
J Photochem Photobiol B; 2017 Jan; 166():18-27. PubMed ID: 27852006
[TBL] [Abstract][Full Text] [Related]
52. The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma.
Hernberg M; Mattila PS; Rissanen M; Hansson J; Aamdal S; Bastholt L; von der Maase H; Schmidt H; Stierner U; Tarkkanen J
J Immunother; 2007 Oct; 30(7):773-9. PubMed ID: 17893569
[TBL] [Abstract][Full Text] [Related]
53. [Underutilization of anticancer agents--an example].
Strannegård O; Thorén FB
Lakartidningen; 2010 Dec 8-14; 107(49):3150; discussion 3150-1. PubMed ID: 21280349
[No Abstract] [Full Text] [Related]
54. Lymphocyte subpopulations and interleukin levels in high-risk melanoma patients treated with high-dose interferon A-2B.
Gogas H; Paterakis G; Frangia K; Bafaloukos D; Pectasides D; Kalofonos HP; Loukopoulos D; Stavropoulou-Giokas C; Ioannovich J; Mihm MC
Am J Clin Oncol; 2002 Dec; 25(6):591-6. PubMed ID: 12478006
[TBL] [Abstract][Full Text] [Related]
55. The use of interferon-alpha in the treatment of cutaneous melanoma: a review.
Punt CJ
Melanoma Res; 1998 Apr; 8(2):95-104. PubMed ID: 9610861
[TBL] [Abstract][Full Text] [Related]
56. Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
Leontovich AA; Dronca RS; Nevala WK; Thompson MA; Kottschade LA; Ivanov LV; Markovic SN;
Melanoma Res; 2017 Feb; 27(1):32-42. PubMed ID: 27824739
[TBL] [Abstract][Full Text] [Related]
57. In vitro lymphocyte stimulation by a soluble antigen from malignant melanoma.
Jehn UW; Nathanson L; Schwartz RS; Skinner M
N Engl J Med; 1970 Aug; 283(7):329-33. PubMed ID: 4193645
[No Abstract] [Full Text] [Related]
58. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma.
Håkansson A; Gustafsson B; Krysander L; Håkansson L
J Interferon Cytokine Res; 1998 Jan; 18(1):33-9. PubMed ID: 9475665
[TBL] [Abstract][Full Text] [Related]
59. Melatonin and Metformin Failed to Modify the Effect of Dacarbazine in Melanoma.
Novik AV; Protsenko SA; Baldueva IA; Berstein LM; Anisimov VN; Zhuk IN; Semenova AI; Latipova DK; Tkachenko EV; Semiglazova TY
Oncologist; 2021 May; 26(5):364-e734. PubMed ID: 33749049
[TBL] [Abstract][Full Text] [Related]
60. Increase in the peripheral lymphocyte populations expressing CD54 (ICAM-1) after hyperthermic isolated limb perfusion in patients with malignant melanoma: an analysis of four cases.
Nakayama J; Guan XC; Tominaga R; Nagae S; Matsuda K; Nakao T; Rikihisa W; Yang HH; Shibata S; Eguchi A; Takeuchi S; Hori Y; Yasui H; Takahashi S
J Dermatol Sci; 1998 May; 17(1):33-8. PubMed ID: 9651826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
